A p21-GFP zebrafish model of senescence for rapid testing of senolytics in vivo.

Both treatments, DQ and navitoclax induced a reduction in p21:GFP bright cells at doses in the same range of what was previously published in cells in vitro, although navitoclax was less effective and did not reach statistical significance.

also in 111,027 other papers